LIFECORE BIOMEDICAL, INC. Finance Lease, Liability, to be Paid, after Year Five
LIFECORE BIOMEDICAL, INC. (LFCR) had Finance Lease, Liability, to be Paid, after Year Five of $5.97 million as of 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Commitment and Contingencies › Finance Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive · last filed 2026-03-16
- 2025-12-31: Finance Lease, Liability, to be Paid, after Year Five $5.97M.
- 2025-09-30: Finance Lease, Liability, to be Paid, after Year Five $5.97M.
- 2025-05-25: Finance Lease, Liability, to be Paid, after Year Five $6.40M.
- 2025-02-23: Finance Lease, Liability, to be Paid, after Year Five $6.40M.
| Period end | Finance Lease, Liability, to be Paid, after Year Five |
|---|---|
| 2025-12-31 | $5.97M 10-KT · filed 2026-03-16 |
| 2025-09-30 | $5.97M 10-Q · filed 2025-11-06 |
| 2025-05-25 | $6.40M 10-K · filed 2025-08-07 |
| 2025-02-23 | $6.40M 10-Q · filed 2025-04-03 |
| 2024-05-26 | $9.00K 10-K · filed 2024-08-26 |
| 2023-05-28 | $0.00 10-K · filed 2024-03-20 |
| 2022-05-29 | $0.00 10-K/A · filed 2023-03-16 |
| 2021-05-30 | $0.00 10-K · filed 2021-07-29 |
| 2020-05-31 | $0.00 10-K · filed 2020-08-14 |
| 2020-02-23 | $2.00K 10-Q · filed 2020-04-03 |
| 2019-11-24 | $2.00K 10-Q · filed 2020-01-02 |
| 2019-08-25 | $2.00K 10-Q · filed 2019-10-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |